These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 21922508)
1. Comparison of fixed dose pegfilgrastim and daily filgrastim after autologous stem cell transplantation in patients with multiple myeloma autografted on a outpatient basis. Ferrara F; Izzo T; Criscuolo C; Riccardi C; Viola A; Delia R; Carbone A; Celentano M Hematol Oncol; 2011 Sep; 29(3):139-43. PubMed ID: 21922508 [TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
3. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. Fenk R; Hieronimus N; Steidl U; Bruns I; Graef T; Zohren F; Ruf L; Haas R; Kobbe G Exp Hematol; 2006 Oct; 34(10):1296-302. PubMed ID: 16982322 [TBL] [Abstract][Full Text] [Related]
4. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bence-Bruckler I; Bredeson C; Atkins H; McDiarmid S; Hamelin L; Hopkins H; Perry G; Genest P; Huebsch L Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693 [TBL] [Abstract][Full Text] [Related]
5. Peripheral blood progenitors mobilised by G-CSF (filgrastim) and reinfused as unprocessed autologous whole blood shorten the pancytopenic period following high-dose melphalan in multiple myeloma. Ossenkoppele GJ; Jonkhoff AR; Huijgens PC; Nauta JJ; van der Hem KG; Dräger AM; Langenhuijsen MM Bone Marrow Transplant; 1994 Jan; 13(1):37-41. PubMed ID: 7517255 [TBL] [Abstract][Full Text] [Related]
6. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma. Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384 [TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial. Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861 [TBL] [Abstract][Full Text] [Related]
8. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients. Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation. Martino M; Gori M; Porto G; Pellicano M; Santoro L; Verduci C; Canale FA; Loteta B; Moscato T; Alati C; Ieracitano MC; Cuzzocrea A; Altomonte M; Florenzano MT; Morabito A; Irrera G; Naso V; Pugliese M; Console G; Ferreri A; Imbalzano L; Tripepi G; Pitino A Ann Hematol; 2023 Jul; 102(7):1915-1925. PubMed ID: 37079070 [TBL] [Abstract][Full Text] [Related]
10. Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. Samaras P; Blickenstorfer M; Siciliano RD; Haile SR; Buset EM; Petrausch U; Mischo A; Honegger H; Schanz U; Stussi G; Stahel RA; Knuth A; Stenner-Liewen F; Renner C Ann Hematol; 2011 Jan; 90(1):89-94. PubMed ID: 20706722 [TBL] [Abstract][Full Text] [Related]
11. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Steidl U; Fenk R; Bruns I; Neumann F; Kondakci M; Hoyer B; Gräf T; Rohr UP; Bork S; Kronenwett R; Haas R; Kobbe G Bone Marrow Transplant; 2005 Jan; 35(1):33-6. PubMed ID: 15531906 [TBL] [Abstract][Full Text] [Related]
13. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation. Zumberg MS; Leather HL; Nejame C; Meyer C; Wingard JR Cytotherapy; 2002; 4(6):531-8. PubMed ID: 12568989 [TBL] [Abstract][Full Text] [Related]
14. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study. Jagasia MH; Greer JP; Morgan DS; Mineishi S; Kassim AA; Ruffner KL; Chen H; Schuening FG Bone Marrow Transplant; 2005 Jun; 35(12):1165-9. PubMed ID: 15880129 [TBL] [Abstract][Full Text] [Related]
15. A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study). Sebban C; Lefranc A; Perrier L; Moreau P; Espinouse D; Schmidt A; Kammoun L; Ghesquieres H; Ferlay C; Bay JO; Lissandre S; Pérol D; Michallet M; Quittet P Eur J Cancer; 2012 Mar; 48(5):713-20. PubMed ID: 22248711 [TBL] [Abstract][Full Text] [Related]
16. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Martino M; Praticò G; Messina G; Irrera G; Massara E; Messina G; Console G; Iacopino P Eur J Haematol; 2006 Nov; 77(5):410-5. PubMed ID: 16930141 [TBL] [Abstract][Full Text] [Related]
17. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688 [TBL] [Abstract][Full Text] [Related]
18. A risk-adapted protocol for delayed administration of filgrastim after high-dose chemotherapy and autologous stem cell transplantation. Khot A; Dickinson M; Stokes K; Harrison S; Burbury K; Fleming S; Wall D; Gambell P; Prince HM; Seymour JF; Ritchie D Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):42-7. PubMed ID: 23146384 [TBL] [Abstract][Full Text] [Related]
19. Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature. Musto P; Scalzulli PR; Terruzzi E; Rossini F; Iacopino P; Messina G; Guariglia R; Pietrantuono G; Villani O; D'Auria F; Falcone A; Sanpaolo G; Valvano MR; Pogliani EM; Morabito F Leuk Res; 2007 Nov; 31(11):1487-93. PubMed ID: 17320951 [TBL] [Abstract][Full Text] [Related]
20. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Weaver CH; Schulman KA; Buckner CD Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]